Q-Line Biotech Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 50.22x | 2,969,200 | 149,116,800 | ₹102 Cr |
| NII (HNI) | 🔥 146.91x | 891,600 | 130,981,200 | ₹31 Cr |
| Retail | 70.27x | 2,079,200 | 146,112,800 | ₹71 Cr |
| Market Maker | — | 313,200 | — | ₹11 Cr |
| Σ Total | 71.75x | 5,940,000 | 426,210,800 | ₹204 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 400 | ₹137,200 |
| Retail (Max) | 13 | 5,200 | ₹1,783,600 |
| S-HNI (Min) | 14 | 5,600 | ₹1,920,800 |
| B-HNI (Min) | 67 | 26,800 | ₹9,192,400 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 237 | 323 | 206 |
| EBITDA | 64 | 71 | 38 |
| Profit After Tax | 39 | 28 | 34 |
| Net Worth | 0 | 190 | 162 |
| Total Assets | 561 | 455 | 339 |
| Reserves & Surplus | 21,288,920 | 188 | 160 |
| Total Borrowing | 244 | 165 | 97 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- To meet working capital requirements – 93.50
- Repayment of certain borrowing availed by the Company, in part or full – 90.00
- General Corporate Purposes –
Company Overview
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks.
Competitive Strengths:
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Experienced Promoter and Management team